Author

Rita Damico Khalid

Observed name: Khalid, Rita Damico

Institution: Kite (United States)

Observed institution: Kite (United States)

OpenAlex ID: A5114055078

Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3

2025 · Bijal D. Shah, Ryan D. Cassaday, et al. · Leukemia · 43

Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3

2023 · Bijal D Shah, Ryan D Cassaday, et al. · Journal for ImmunoTherapy of Cancer · 34

Five-Year Outcomes of Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Treated with Brexucabtagene Autoleucel (Brexu-cel) in ZUMA-2 Cohorts 1 and 2

2024 · Michael Wang, Andre Goy, et al. · Blood · 11

Brexucabtagene autoleucel for BTKi-naive relapsed/refractory mantle cell lymphoma: primary analysis of ZUMA-2 cohort 3

2025 · Tom van Meerten, Marie José Kersten, et al. · Blood · 10

Primary Analysis of ZUMA-2 Cohort 3: Brexucabtagene Autoleucel (Brexu-Cel) in Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Who Were Naive to Bruton Tyrosine Kinase Inhibitors (BTKi)

2024 · Tom van Meerten, M.J. Kersten, et al. · Blood · 6

Long-term survival outcomes of patients (pts) with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-3.

2024 · Olalekan O. Oluwole, Armin Ghobadi, et al. · Journal of Clinical Oncology · 4

Outcomes of patients aged ≥26 years with relapsed or refractory B-cell acute lymphoblastic leukemia in ZUMA-3 and historical trials

2024 · Monique C. Minnema, Xiang Yin, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 4

Real-World (RW) Outcomes for Brexucabtagene Autoleucel (Brexu-Cel) Treatment in Patients (Pts) with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) By High-Risk Features and Prior Treatments: Updated Evidence from the CIBMTR® Registry

2024 · Kitsada Wudhikarn, Evandro Bezerra, et al. · Blood · 3

Impact of age, prior therapies, and subsequent transplant on long-term outcomes of adults with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-3.

2023 · Bijal D. Shah, Ryan Daniel Cassaday, et al. · Journal of Clinical Oncology · 3

P367: Long-term Outcomes of Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia Treated With Brexucabtagene Autoleucel in Zuma-3 by Age, Prior Therapies, and Subsequent Transplant

2023 · Bijal Shah, Ryan D. Cassaday, et al. · HemaSphere · 2

Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2

2026 · Javier Muñoz, Frederick L. Locke, et al. · Journal of Hematology & Oncology · 1

Additional file 1 of Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2

2026 · Muñoz, Javier, Locke, Frederick L., et al. · Figshare

Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2

2026 · Muñoz, Javier, Locke, Frederick L., et al. · Figshare

Two-year update of ZUMA-2 Cohort 3: Brexucabtagene autoleucel (Brexu-cel) in patients (pts) with relapsed/refractory mantle cell lymphoma (R/R MCL) who had not received prior Bruton tyrosine kinase inhibitor (BTKi) therapy

2025 · Tom Van Meerten, Marie José Kersten, et al. · Blood

Endogenous regulation of inflammatory response as a determinant of durable remission without stem cell transplant following brexucabtagene autoleucel (Brexu-cel) therapy in ALL

2025 · Sabina Adhikary, Colleen Schweitzer, et al. · Blood

Impact of Disease Burden, CAR-T Expansion, and Mononuclear Cell Recovery on Overall Response and Duration of Response in Zuma-3 Pivotal Study

2024 · Sabina Adhikary, Colleen Schweitzer, et al. · Blood

Works count: 16

Citation count: 120

H-index: 5

I10-index: 4